{"slug":"brain","tag":"brain","variants":["brain"],"description":"No description yet","count":9,"kinds":{"person":9},"related":[{"slug":"trialist","tag":"trialist","shared":9},{"slug":"paediatric","tag":"paediatric","shared":4},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":2},{"slug":"radiotherapy","tag":"radiotherapy","shared":1},{"slug":"rare-cancers","tag":"rare-cancers","shared":1}],"records":[{"id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","tldr":"Mayo Clinic radiation oncologist whose trials showed that focused radiosurgery preserves thinking and memory better than whole-brain radiotherapy for brain metastases, and that sparing the hippocampus reduces cognitive harm when whole-brain treatment is needed."},{"id":"jan-buckner","kind":"person","name":"Jan C. Buckner","route":"/people/jan-buckner/","tldr":"Mayo Clinic neuro-oncologist who was lead author of the long-term RTOG 9802 results, which showed that adding PCV chemotherapy to radiotherapy roughly doubles survival in high-risk low-grade glioma."},{"id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","route":"/people/scott-plotkin/","tldr":"Boston neuro-oncologist who showed that bevacizumab can shrink vestibular schwannomas and restore hearing in people with neurofibromatosis type 2."},{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","tldr":"New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival."},{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","tldr":"Marseille neuro-oncologist who was lead author of AVAglio, the trial that showed adding bevacizumab to standard glioblastoma treatment delays progression but does not lengthen life."},{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","tldr":"Paris paediatric neuro-oncologist who led HERBY, the trial that showed adding bevacizumab does not help children with high-grade glioma, and who leads European trials in diffuse midline glioma."},{"id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","tldr":"London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma."},{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","tldr":"Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy."},{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/","tldr":"Seattle paediatric neuro-oncologist who led COG ACNS0332, the trial that found adding carboplatin to radiotherapy improves survival in children with high-risk group 3 medulloblastoma but isotretinoin does not help."}]}